YM 298198 hydrochloride

Discontinued Product

2448 has been discontinued.

View all Glutamate (Metabotropic) Group I Receptors products.
说明: Highly potent, selective non-competitive mGlu1 antagonist
化学名: 6-Amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide hydrochloride
纯度: ≥99% (HPLC)
说明书
引用文献 (1)
评论
文献 (5)

生物活性 for YM 298198 hydrochloride

YM 298198 hydrochloride is a non-competitive antagonist with high affinity and selectivity for mGlu1 receptors (Ki = 19 nM); inactive at other mGlu receptor subtypes (mGlu2-7), ionotropic receptors and glutamate transporters (IC50 > 10 μM). Inhibits glutamate-induced IP production more potently than CPCCOEt (IC50 values are 16 nM and 6.3 μM respectively), and is orally active in vivo, demonstrating an antinociceptive effect in hyperalgesic mice.

Desmethyl Derivative also available.

许可信息

Sold with the permission of Astellas Pharma Inc.

技术数据 for YM 298198 hydrochloride

分子量 378.92
公式 C18H22N4OS.HCl
储存 Desiccate at +4°C
纯度 ≥99% (HPLC)
CAS Number 1216398-09-2
PubChem ID 45073464
InChI Key WYTJVUVCSUWZTH-UHFFFAOYSA-N
Smiles Cl.CN(C1CCCCC1)C(=O)C1=C(C)N2C(S1)=NC1=CC=C(N)C=C21

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for YM 298198 hydrochloride

关键词: YM 298198 hydrochloride, YM 298198 hydrochloride supplier, potent, selective, non-competitive, mGlu1, mGluR1, antagonists, Group, I, Receptors, Glutamate, Metabotropic, YM298198, hydrochloride, (Metabotropic), 2448, Tocris Bioscience

1 篇 YM 298198 hydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。 YM 298198 hydrochloride 的部分引用包括:

Yasuda et al (2018) Drebrin Isoforms Critically Regulate NMDAR- and mGluR-Dependent LTD Induction. Front Cell Neurosci 12 330 PMID: 30349460


YM 298198 hydrochloride 的评论

目前没有该产品的评论。 Be the first to review YM 298198 hydrochloride and earn rewards!

Have you used YM 298198 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.